Cara Therapeutics (CARA) Misses Q2 EPS by 6c

Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.48), $0.06 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $79 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge